Indivior PLC (LON:INDV) has thrown out its guidance for the full year as the coronavirus pandemic caused a decline in patient numbers for its drugs.
The pharmaceutical firm said in an update on Wednesday that the pandemic had resulted in a “meaningful decline” in enrolments for its SUBLOCADE and PERSERIS injections and the market share strength of its SUBOXONE opioid dependency treatment.
READ: Indivior expects to swing to 2020 loss as Suboxone sales keep falling
Indivior said it believed the impacts largely reflected “general trends of substantial reductions in patient visits to healthcare provider offices and a corresponding increase in remote prescribing”.
The company added that as a result of the uncertainty it does not expect to be able to provide revised guidance “until the duration and extent of the market disruptions from the [coronavirus] pandemic are known”.
Shares in Indivior slipped 0.9% to 43.6p in early trading on Wednesday.